A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist CG301360 Alleviates Insulin Resistance and Lipid Dysregulation in db/db Mice

Activation of peroxisome proliferator-activated receptors (PPARs) have been implicated in the treatment of metabolic disorders with different mechanisms; PPARα agonists promote fatty acid oxidation and reduce hyperlipidemia, whereas PPARγ agonists regulate lipid redistribution from visceral fat to subcutaneous fat and enhance insulin sensitivity. To achieve combined benefits from activated PPARs on lipid metabolism and insulin sensitivity, a number of PPARα/γ dual agonists have been developed. However, several adverse effects such as weight gain and organ failure of PPARα/γ dual agonists have been reported. By use of virtual ligand screening, we identified and characterized a novel PPARα/γ dual agonist, (R)-1-(4-(2-(5-methyl-2-p-tolyloxazol-4-yl)ethoxy)benzyl)piperidine-2-carboxylic acid (CG301360), exhibiting the improvement in insulin sensitivity and lipid metabolism. CG301360 selectively stimulated transcriptional activities of PPARα and PPARγ and induced expression of their target genes in a PPARα- and PPARγ-dependent manner. In cultured cells, CG301360 enhanced fatty acid oxidation and glucose uptake and it reduced pro-inflammatory gene expression. In db/db mice, CG301360 also restored insulin sensitivity and lipid homeostasis. Collectively, these data suggest that CG301360 would be a novel PPARα/γ agonist, which might be a potential lead compound to develop against insulin resistance and hyperlipidemia.

[1]  Armin Ruf,et al.  Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists , 2009, ChemMedChem.

[2]  J. B. Kim,et al.  Berberine suppresses proinflammatory responses through AMPK activation in macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[3]  M. Lane,et al.  Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.

[4]  Jason K. Kim,et al.  Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.

[5]  U. Andersson,et al.  Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats , 2007 .

[6]  Samuel M. Cohen,et al.  Rodent Carcinogenicity Profile of the Antidiabetic Dual PPAR α and γ Agonist Muraglitazar , 2007 .

[7]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[8]  S. Roy,et al.  Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema? , 2007 .

[9]  J. Rosenstock,et al.  Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trial*† , 2006 .

[10]  E. Kang,et al.  The long‐term effects of rosiglitazone on serum lipid concentrations and body weight , 2006, Clinical endocrinology.

[11]  M. J. Yoon,et al.  Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator–Activated Receptor α , 2006, Diabetes.

[12]  A. Bross,et al.  Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice , 2005, International Journal of Obesity.

[13]  Jong Bae Seo,et al.  Activated Liver X Receptors Stimulate Adipocyte Differentiation through Induction of Peroxisome Proliferator-Activated Receptor γ Expression , 2004, Molecular and Cellular Biology.

[14]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[15]  Weimin He,et al.  Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[17]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[18]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[19]  B. Hoogwerf,et al.  Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. , 2003, Journal of the American College of Cardiology.

[20]  N. Hewitt,et al.  Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. , 2002, Chemico-biological interactions.

[21]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[22]  M. Kasuga,et al.  Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. , 2002, Diabetes.

[23]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[24]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[25]  R. Saladin,et al.  Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. , 2000, Biochemical and biophysical research communications.

[26]  L. Madsen,et al.  PPARa activators improve insulin sensitivity and reduce adiposity , 2000 .

[27]  M. Mittal,et al.  Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report , 2000, Annals of Internal Medicine.

[28]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[29]  I. Hirsch,et al.  Pulmonary edema associated with troglitazone therapy. , 1999, Archives of internal medicine.

[30]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[31]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[32]  Y. Yazaki,et al.  A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. , 1998, Diabetes.

[33]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[34]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[35]  E. Bruckert,et al.  Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[37]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[38]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[39]  S. Roy,et al.  Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? , 2007, British journal of pharmacology.

[40]  U. Andersson,et al.  Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  S. Tannehill-Gregg,et al.  Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  R. Gregg,et al.  Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. , 2006, Diabetes.

[43]  J. Rosenstock,et al.  Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. , 2006, Current medical research and opinion.

[44]  Michael Cap,et al.  Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice , 2006 .

[45]  이현철,et al.  The long-term effects of rosiglitazone on serum lipid concentrations and body weight , 2006 .

[46]  R. Evans,et al.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. , 2003, Cell.

[47]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[48]  W. Wahli,et al.  Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. , 1999, The Journal of clinical investigation.

[49]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.